Engineered immune cells take on liver cancer in new trial
NCT ID NCT04864054
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment called ECT204 for adults with advanced liver cancer that has not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 60 people to check if the therapy is safe and whether it can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ECT204 T cells (a type of immune cell therapy made from the patient's own blood)
What this could lead to
If it works, this could offer a new treatment option for people with advanced liver cancer who have run out of standard therapies.
What could go wrong
This is an early-phase trial with only 60 participants, so the therapy may not work or could cause serious side effects. It is not a cure and long-term safety is unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fred Hutchinson Cancer Center, University of Washington
RECRUITINGSeattle, Washington, 98109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Kansas University Medical Center, Principal Investigator:
COMPLETEDWestwood, Kansas, 66205, United States
-
Montefiore Einstein Comprehensive Cancer Center
RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
National Taiwan University Cancer Center
RECRUITINGTaipei, 106, Taiwan
Contact
Contact Email: •••••@•••••
-
Oregon Health and Sciences University
RECRUITINGPortland, Oregon, 97239, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Roswell Park Comprehensive Cancer Center
COMPLETEDBuffalo, New York, 14263, United States
-
University of Texas Southwestern, Harold C. Simmons Comprehensive Cancer Center
RECRUITINGDallas, Texas, 75235, United States
Contact Email: •••••@•••••
Contact
Contact